In their previous filing dated November 17, 2022 they reported 1,265,823 shares and 4.39% of the company, an increase in shares of 89.36% and an increase in total ownership of 3.93% (calculated as current – previous percent ownership).
Entera is a leader in the development of orally delivered large molecule therapeutics for use in areas with significant unmet medical need where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients.
The Company’s proprietary, oral drug delivery technology is designed to address the technical challenges of poor absorption, high variability, and the inability to deliver large molecules to the targeted location in the body through the use of a synthetic absorption enhancer to facilitate the absorption of large molecules, and protease inhibitors to prevent enzymatic degradation and support delivery to targeted tissues.
The Company’s most advanced product candidates, EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are in Phase 2 clinical development. Entera also licenses its technology to biopharmaceutical companies for use with their proprietary compounds and, to date, has established a collaboration with Amgen Inc.
What are other large shareholders doing?
Knoll Capital Management, LLC holds 2,484,275 shares representing 8.62% ownership of the company. No change in the last quarter.
Ra Capital Management, L.p. holds 2,082,372 shares representing 7.23% ownership of the company. In it’s prior filing, the firm reported owning 2,353,000 shares, representing a decrease of 13.00%. The firm decreased its portfolio allocation in ENTX by 44.61% over the last quarter.
Renaissance Technologies Llc holds 21,300 shares representing 0.07% ownership of the company. In it’s prior filing, the firm reported owning 0 shares, representing an increase of 100.00%.
Geode Capital Management, Llc holds 17,597 shares representing 0.06% ownership of the company. No change in the last quarter.
Altium Wealth Management LLC holds 11,830 shares representing 0.04% ownership of the company. No change in the last quarter.
What is the overall Fund Sentiment?
There are 15 funds or institutions reporting positions in Entera Bio Ltd. This is a decrease of 0 owner(s) or 0.00%.
Average portfolio weight of all funds dedicated to Entera Bio Ltd is 0.1113%, a decrease of 17.2908%. Total shares owned by institutions decreased in the last three months by 10.02% to 4,657,733 shares.
Fintel’s Fund Sentiment Score is a quantitative model that ranks companies from zero to 100 based on Fund Sentiment. Fund Sentiment is important because it tells you if funds are buying or selling – and in particular how the company ranks compared to other companies in the investing universe.
This article originally appeared on Fintel
Sponsored: Tips for Investing
A financial advisor can help you understand the advantages and disadvantages of investment properties. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. If you’re ready to find an advisor who can help you achieve your financial goals, get started now.
Investing in real estate can diversify your portfolio. But expanding your horizons may add additional costs. If you’re an investor looking to minimize expenses, consider checking out online brokerages. They often offer low investment fees, helping you maximize your profit.